Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from 3D Medicines, Inc. ( (HK:1244) ).
3D Medicines reported audited 2025 annual results highlighting both operational challenges and strategic progress as Hong Kong’s biotech capital markets showed signs of recovery. Envafolimab, its first commercialized PD-L1 inhibitor, generated RMB356.1 million in sales in China, a 20.1% year-on-year decline attributed to bank account freezes linked to litigation in Qingdao that disrupted inventory supply, although the company expects sales to recover with new indications and resumed distribution.
During the year, Envafolimab gained further clinical traction with its 20th domestic guideline recommendation and 11 research presentations at the 2025 ASCO meeting, reinforcing its medical profile. The company also accelerated its global push by initiating a broad commercialization strategy, including a licensing deal with Glenmark and ongoing out-licensing talks in additional markets.
On the R&D side, 3D Medicines advanced its radionuclide drug conjugates platform, progressing a wholly proprietary 177Lu-labeled PSMA-targeted candidate into investigator-initiated trials and moving a FAP-targeted program through pre-clinical evaluation. These differentiated RDC assets aim to position the firm in next-generation radiopharmaceutical oncology therapies, with multiple additional projects in early discovery.
The company rapidly built an AI-enabled LNP-mRNA platform over roughly two years, assembling a 30-plus scientist team in Shanghai and Beijing to develop mRNA cancer vaccines and in vivo CAR-T candidates with global intellectual property rights. Lead mRNA therapeutic vaccine 3D124 and follow-up programs such as SCLC-targeted 3D125 and mRNA-based in vivo CAR-T initiatives underscore a strategic shift toward preventing tumor metastasis and recurrence, supporting a dual engine of revenue from commercialization and long-term growth from innovation.
The most recent analyst rating on (HK:1244) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on 3D Medicines, Inc. stock, see the HK:1244 Stock Forecast page.
More about 3D Medicines, Inc.
3D Medicines Inc. is an innovation-driven biopharmaceutical company focused on oncology, currently in the commercialization phase. Its primary products and platforms include Envafolimab, a subcutaneously injectable PD-L1 inhibitor in China, alongside proprietary radionuclide drug conjugates, AI-driven LNP-mRNA technologies, and in vivo CAR programs aimed at global cancer therapy markets.
Average Trading Volume: 101,796
Technical Sentiment Signal: Sell
Current Market Cap: HK$1B
See more insights into 1244 stock on TipRanks’ Stock Analysis page.